Brokers Set Expectations for Cadrenal Therapeutics, Inc.’s Q3 2024 Earnings (NASDAQ:CVKD)

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) – Equities research analysts at Zacks Small Cap issued their Q3 2024 earnings per share estimates for shares of Cadrenal Therapeutics in a report released on Monday, September 16th. Zacks Small Cap analyst D. Bautz anticipates that the company will post earnings per share of ($2.18) for the quarter. The consensus estimate for Cadrenal Therapeutics’ current full-year earnings is ($6.00) per share. Zacks Small Cap also issued estimates for Cadrenal Therapeutics’ Q4 2024 earnings at ($2.18) EPS, FY2024 earnings at ($8.17) EPS, FY2025 earnings at ($2.90) EPS and FY2026 earnings at ($2.20) EPS.

Cadrenal Therapeutics (NASDAQ:CVKD) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($2.25) earnings per share for the quarter, beating analysts’ consensus estimates of ($19.04) by $16.79.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $0.20 price target on shares of Cadrenal Therapeutics in a research note on Thursday, June 6th.

Cadrenal Therapeutics Stock Up 1.4 %

Shares of NASDAQ CVKD opened at $11.98 on Wednesday. The stock has a market capitalization of $191.78 million, a price-to-earnings ratio of -38.65 and a beta of 1.74. Cadrenal Therapeutics has a 1 year low of $5.40 and a 1 year high of $32.55.

Cadrenal Therapeutics Company Profile

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome.